Physician profile
Bruce D Schweiger
NPI 1407958481
$1,996.46
in general payments reported to CMS, 2019-2025
15 companies · $30.32 in 2025
The $30.32 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,524 · 2020: $278 · 2022: $55.95 · 2023: $16.31 · 2024: $91.87 · 2025: $30.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $138.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $404.40 | 2019-2020 | |
| Allergan, INC. | $306.86 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $260.60 | 2019-2020 | |
| Abbvie INC. | $182.54 | 2022-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $175.54 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $165.44 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $128.80 | 2019 | |
| Vanda Pharmaceuticals INC. | $115.54 | 2019 | |
| Shire North American Group INC | $99.65 | 2019 | |
| Neurocrine Biosciences, INC. | $53.79 | 2019 | |
| Jazz Pharmaceuticals INC. | $40.71 | 2019-2020 | |
| Lundbeck LLC | $21.13 | 2020 | |
| Aytu Biopharma, INC. | $15.20 | 2019 | |
| Alkermes, INC. | $14.35 | 2019 | |
| Bausch Health US, LLC | $11.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Schweiger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.